Big pharma players including Novartis, Roche, Pfizer, Sanofi are embracing digital technologies to deliver better to the patients.
FDA’S 2018 Strategic Policy Roadmap indicates increasing number of digital health clearances in coming times with revised regulatory processes.
Novartis bets high by acquiring the non-earning US-based gene therapy firm AveXis for $8.7 billion. But, AveXis' novel gene therapy- AVXS-101 could be a “game-changing” treatment for SMA patients and could turn out to be a potential blockbuster for Novartis, if approved.
KEY POINTS Breath Biopsy analyzes individual’s breath for biomarkers, signifying the metabolic conditions and cancer diagnosis of the person. GlaxoSmithKline ...
KEY POINTS Praluent is a cholesterol-lowering monoclonal antibody, significantly reduces the combined risk of cardiovascular problems and related deaths in ...